Previous close | 76.00 |
Open | 76.00 |
Bid | 76.00 x N/A |
Ask | 77.50 x N/A |
Day's range | 76.00 - 76.00 |
52-week range | 65.50 - 93.50 |
Volume | |
Avg. volume | 0 |
Market cap | 3.777B |
Beta (5Y monthly) | 0.88 |
PE ratio (TTM) | 24.44 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 1.47 (1.93%) |
Ex-dividend date | 30 Aug 2024 |
1y target est | N/A |
WILMINGTON, Del., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today announced it has completed the sale of its nutraceuticals business to an affiliate of Turnspire Capital Partners LLC (“Turnspire”) effective August 30, 2024. The sale includes custom formulation and contract manufacturing capabilities for the nutrition market from the production facilities in New Jersey and Utah in the United States, and Tamaulipas, Mexico. Financial terms of the transaction were not disclosed. “
WILMINGTON, Del., Aug. 09, 2024 (GLOBE NEWSWIRE) -- The board of directors of Ashland Inc. (NYSE: ASH) has declared a quarterly cash dividend of $0.405 cents per share on the company's common stock. The dividend is payable on September 15, 2024, to stockholders of record at the close of business on September 1, 2024. As of July 31, 2024, there were 48,832,846 shares of Ashland common stock outstanding. About Ashland Ashland Inc. (NYSE: ASH) is a global additives and specialty ingredients company
Sales of $544 millionNet income (including discontinued operations) of $6 million, or $0.12 per diluted shareIncome from continuing operations of $31 million, or $0.60 per diluted shareAdjusted income from continuing operations excluding intangibles amortization expense of $75 million, or $1.49 per diluted shareAdjusted EBITDA of $139 million, up five percent from the prior-year quarterCash flows provided by operating activities of $128 million; ongoing free cash flow2 of $112 millionRepurchased